Media

Daiichi Sankyo, Inc. Announces Sale of Pharmaceutical Packaging Plant in Bethlehem, PA

Download the PDF version of Article

April 03, 2017

Parsippany, NJ – April 3, 2017 – Daiichi Sankyo, Inc. (“the Company”) announced today that Sharp Packaging Services, a division of UDG Healthcare, plc (“Sharp”) has purchased the Daiichi Sankyo pharmaceutical packaging plant located in Bethlehem, PA (“the Plant”). The transaction closed on April 1, 2017, at which time Sharp took over operations at the Plant.  Sharp is now packaging several of Daiichi Sankyo, Inc. medications in Bethlehem. Sharp has also offered the Plant’s workers opportunities for employment. Detailed financial terms are not being disclosed. 

As Daiichi Sankyo, Inc. continues to re-orient its business focus towards the specialized areas of oncology and pain, it is moving to an outsourced packaging model for its medications as part of its ongoing efforts to stay flexible and aligned with customer demands.

“We are particularly gratified to identify a new packaging partner that will continue employing the dedicated and talented workers at the Bethlehem facility,” said Ken Keller, President, Administrative and Commercial, Daiichi Sankyo, Inc. “Selling the Plant to an organization that can maximize the facility is also the best long-term solution for our customers, our company, and the viability of the Plant. With its track record as a leader in contract packaging and clinical supply services for pharmaceutical companies, as well as its expertise in implementing serialisation solutions, Sharp is the right partner to assume our packaging operations.”

Overview of the Plant:

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.